Breaking News Instant updates and real-time market news.

QCOM

Qualcomm

$57.46

0.63 (1.11%)

08:52
01/14/19
01/14
08:52
01/14/19
08:52

Qualcomm price target cut to $60 from $68 at Evercore ISI

Evercore ISI analyst C.J. Muse cut his price target for Qualcomm (QCOM) to $60 from $68 and maintained an In Line rating, saying he expects to get clarity on the litigation with Apple (AAPL) early this year. Muse tells investors in a research note that a favorable outcome likely results in $5B in catch-up royalty payments, with $1.85B in Apple run-rate royalty payments, adding $1.30 to run-rate EPS, while an unfavorable outcome likely forces Qualcomm to license to other chipmakers and could lead to renegotiating license terms with major handset OEMs. Near-term, the analyst sees normal seasonality and weak smartphone markets pressuring units, and FX headwinds due to the strong dollar, which likely creates revenue headwinds into 1H.

QCOM Qualcomm
$57.46

0.63 (1.11%)

12/21/18
JPMS
12/21/18
NO CHANGE
JPMS
Overweight
JPMorgan sees minimal financial impact to Apple from Germany injunction
JPMorgan analyst Samik Chatterjee sees a minimal financial impact to Apple (AAPL) after the District Court of Munich in Germany issued a permanent injunction against the company relative to the infringement of a Qualcomm (QCOM) hardware patent and has restricted Apple from selling specific iPhones in the country. The analyst estimates that the financial impact of Apple's stop-sale is likely minimal given that Germany accounts for only 3% of its total global shipments. Further, Apple owns only 15 stores in the whole of Germany, Chatterjee tells investors in a research note. He would expect the impact to be less than 1M shipments on an annualized basis. The analyst keeps an Overweight rating on Apple.
12/21/18
ARGS
12/21/18
NO CHANGE
ARGS
Buy
German ruling may increase pressure on Apple to settle with Qualcomm, says Argus
Argus analyst Jim Kelleher said the recent German patent ruling, coupled with an earlier Chinese ruling, could increase pressure on Apple (AAPL) to settle its legal fight with Qualcomm (QCOM), adding that he believes Qualcomm being willing to consider changes to its percentage-of-device-price revenue model is "the one thing that could push a settlement forward." The analyst, who sees it as only a matter of time before this royalty model is adjusted, keeps a Buy rating on Qualcomm shares.
12/24/18
WEDB
12/24/18
NO CHANGE
Target $275
WEDB
Outperform
Wedbush lays out Apple investor 'Christmas wish list' for 2019
Wedbush analyst Daniel Ives said that sentiment about Apple (AAPL) "is as negative as we have seen in many years" with the stock down over 30% since early November, though he "vehemently" disagrees with those who are pricing in a "meaningful apocalyptic iPhone unit deceleration not just for 2019 but possibly for 2020." With Apple investors looking toward 2019, Ives laid out his "Top 10 holiday wish list for Apple investors," which includes FY19 iPhone units shipped topping 200M; China consumer iPhone upgrades for FY19 hitting 30M; settling the Qualcomm (QCOM) patent issue "once and for all"; services business hits revenue over $45B in FY19; more transparency and metrics around the services business; a meaningful acquisition of a major content player; announcing an accelerated buyback program; lowering prices on some OLED iPhone models; the China trade war being settled in early 2019; and Apple announcing a strategic partnership with Tesla (TSLA). Ives keeps an Outperform rating and $275 price target on Apple shares.
01/03/19
ADAM
01/03/19
NO CHANGE
Target $75
ADAM
Buy
FTC case could lead to settlement between Qualcomm and Apple, says Canaccord
Canaccord analyst T. Michael Walkley said the upcoming FTC case is an important step in the process towards Qualcomm (QCOM) and Apple (AAPL) reaching a licensing settlement. The analyst noted that in a partial summary judgment, it required Qualcomm to license cellular standard-essential patents to the Alliance for Telecommunications Industry Standards, presenting potential risks to its licensing practices. Walkley maintains his Buy rating and $75 price target on Qualcomm shares.

TODAY'S FREE FLY STORIES

IMMU

Immunomedics

$13.31

-4.75 (-26.30%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Downgrade
Immunomedics rating change  »

Immunomedics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$13.31

-4.75 (-26.30%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Downgrade
Immunomedics rating change  »

Correction: Immunomedics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$4.92

0.015 (0.31%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Recommendations
GoPro analyst commentary  »

GoPro still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 25

    Feb

07:25
01/22/19
01/22
07:25
01/22/19
07:25
General news
FX Update »

FX Update: A generally…

SRNE

Sorrento Therapeutics

$2.30

0.04 (1.77%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Hot Stocks
Sorrento Therapeutics announces interim RTX study data »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

, SNY

Sanofi

$41.50

-0.54 (-1.28%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Recommendations
Lexicon, Sanofi analyst commentary  »

Lexicon price target…

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

SNY

Sanofi

$41.50

-0.54 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

FTNT

Fortinet

$70.50

-2.1 (-2.89%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Downgrade
Fortinet rating change  »

Fortinet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

  • 25

    Feb

ATI

Allegheny Technologies

$25.48

0.5 (2.00%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Earnings
Allegheny Technologies reports Q4 EPS 30c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IRMD

iRadimed

$25.77

0.32 (1.26%)

07:21
01/22/19
01/22
07:21
01/22/19
07:21
Hot Stocks
iRadimed suspends sales of 3880 patient vital signs monitoring system »

iRadimed announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AINV

Apollo Investment

$14.51

-0.01 (-0.07%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Upgrade
Apollo Investment rating change  »

Citi upgrades Apollo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

FITB

Fifth Third

$27.00

0.59 (2.23%)

, MBFI

MB Financial

$44.59

0.83 (1.90%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Hot Stocks
Fifth Third sees FY19 NII up approx. 3% from FY18 »

Sees Q1 NII down 1.5%-2%…

FITB

Fifth Third

$27.00

0.59 (2.23%)

MBFI

MB Financial

$44.59

0.83 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

ICE

IntercontinentalExchange

, CME

CME Group

$183.47

2.25 (1.24%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Recommendations
IntercontinentalExchange, CME Group analyst commentary  »

Citi upgrades ICE to Buy,…

ICE

IntercontinentalExchange

CME

CME Group

$183.47

2.25 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 08

    May

  • 28

    May

MO

Altria Group

$48.29

1.22 (2.59%)

, PM

Philip Morris

$73.77

1.25 (1.72%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Downgrade
Altria Group, Philip Morris rating change  »

Altria Group downgraded…

MO

Altria Group

$48.29

1.22 (2.59%)

PM

Philip Morris

$73.77

1.25 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 18

    Feb

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

, AGN

Allergan

$160.28

3.74 (2.39%)

07:16
01/22/19
01/22
07:16
01/22/19
07:16
Periodicals
Aurinia CEO says VOS could become blockbuster treatment, STATNews reports »

Though Aurinia…

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

AGN

Allergan

$160.28

3.74 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 18

    May

  • 28

    May

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Recommendations
Amazon.com analyst commentary  »

Amazon.com remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Hot Stocks
Crispr Therapeutics signs collaboration agreement with ProBioGen »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$164.13

3.78 (2.36%)

07:13
01/22/19
01/22
07:13
01/22/19
07:13
Initiation
Constellation Brands initiated  »

Constellation Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

HBM

Hudbay Minerals

$5.65

0.03 (0.53%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Hudbay Minerals rating change  »

Hudbay Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Crispr Therapeutics rating change  »

Citi downgrades Crispr…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

$1.92

-0.05 (-2.54%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

FB

Facebook

$150.01

1.77 (1.19%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Periodicals
VC says Facebook the most 'vulnerable' big tech firm, CNBC reports »

Facebook is the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Hot Stocks
Peoples Bancorp reports Q4 net interest margin 3.77% vs. 3.68% sequentially »

Compared to 3.63% for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

AXGN

AxoGen

$16.00

0.64 (4.17%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Hot Stocks
AxoGen appoints Eric Sandberg CCO »

AxoGen (AXGN) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Earnings
Peoples Bancorp reports Q4 EPS 71c, consensus 67c »

Earnings per diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CTSO

CytoSorbents

$7.66

0.04 (0.52%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Hot Stocks
CytoSorbents expands partnership with Fresenius Medical Care to Korea and Mexico »

CytoSorbents announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.